Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment.

ABSTRACT: In patients with renal impairment (n = 22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

SUBMITTER: Souza E 

PROVIDER: S-EPMC7179609 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature